Alzheimer's Biomarker Testing Raises Ethical Concerns
A new JAMA viewpoint highlights the risks of testing for Alzheimer's biomarkers in adults who show no symptoms.
Updated on Oct. 20, 2026 in Alzheimer’s
Live Poll
Would you want to know if you are at risk for a disease before symptoms appear?
On Oct. 19, 2026, Dr. Gayatri Devi published an analysis in JAMA discussing the ethical implications of using Alzheimer's biomarker testing on symptom-free adults. The report underscores that positive results indicate a higher risk rather than a definitive prognosis.
Why it matters
The analysis highlights that individuals labeled with Alzheimer's through biomarker testing face significant, unresolved risks regarding long-term insurance and employment. Because no approved treatment currently exists for symptom-free patients, early detection poses major psychological and financial dilemmas.
A study of 499 adults found a 91.7% match rate between blood test results and traditional diagnostic tests. These tests are authorized only for adults 55 and older with cognitive symptoms, not as stand-alone screens.
The players
Dr. Gayatri Devi
She is a medical researcher and expert based in New York who authored the JAMA viewpoint on Alzheimer's diagnostic ethics.
Alzheimer's Association
This is a non-profit organization that leads efforts in Alzheimer's care, support, and research, including the development of diagnostic workgroup definitions.
Food and Drug Administration
This is the federal agency responsible for protecting public health by regulating medical devices and diagnostic tests for safety and effectiveness.
The details
Physicians utilize these tests to identify brain changes linked to Alzheimer's, but concerns persist over the lack of protection under the Genetic Information Nondiscrimination Act for life, disability, or long-term care insurance. Disagreements continue between the Alzheimer's Association and the International Working Group over whether asymptomatic individuals should officially be classified with the disease.
Timeline
2024: Medical workgroups proposed conflicting definitions for Alzheimer's disease.
May 2025: The FDA cleared the first Alzheimer's blood test for adults 55 and older with cognitive symptoms.
Oct. 19, 2026: Dr. Gayatri Devi published a Viewpoint in JAMA regarding ethical implications of testing.
The Big Picture
The Genetic Information Nondiscrimination Act limits how employers and insurers use genetic data, providing a key benchmark for the patient privacy concerns raised in this story. The analysis marks a clear departure from these protections, as the law currently fails to cover the life and long-term care insurance sectors.
Patients should recognize that positive biomarker tests do not confirm a future Alzheimer's diagnosis and may carry unintended insurance consequences. Since these tests lack universal clinical approval for asymptomatic screening, individuals should consult doctors about the necessity of testing.
The takeaway
Patients should approach biomarker testing with caution, as early knowledge may result in insurance vulnerabilities without current therapeutic benefits. Understanding the limitations of diagnostic tools is essential for making informed long-term healthcare and financial decisions.
Further reading
Learn more about evolving diagnostic standards in the United States Alzheimer’s section.
Live Poll
Would you want to know if you are at risk for a disease before symptoms appear?
